Switch to:
More From Other Websites
Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer Jan 17 2017
Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
The Three Most Important Questions For TESARO Inc (TSRO) Shareholders Right Now Jan 13 2017
TESARO Varubi IV Gets Complete Response Letter in the U.S. Jan 13 2017
Coverage initiated on Tesaro by Morgan Stanley Jan 13 2017
Tesaro Stock Rebounds Despite FDA Holdup On Anti-Nausea Med Jan 12 2017
TESARO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 12 2017
Latest drug by Waltham drugmaker Tesaro rejected by FDA Jan 12 2017
TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA Jan 11 2017
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal Jan 10 2017
TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition Jan 09 2017
6 Major FDA Decisions and Biopharma Catalysts Coming in January and February Jan 06 2017
What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO) Jan 03 2017
Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains? Dec 30 2016
Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains? Dec 30 2016
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
Let’s call this the no-fault stock market Dec 29 2016
Take-Two A Top Pick, Tesaro A Buy, Ritchie Bros. Downgraded Dec 27 2016
The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen Dec 23 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK